Rediscover

MyRisk®

Hereditary Cancer Test

The most accurate germline test
to help guide surgical decisions

MyRisk STAT is now available to even more patients meeting criteria



Myriad® genetics

MyRisk®
Hereditary Cancer Test

Comprehensive accuracy at the speed of care

Your patients need your treatment guidance, fast

Feeling the pressure of time, every cancer patient looks to you for clear next steps. MyRisk draws on Myriad's 30+ years of genetic expertise to analyze 48 clinically actionable genes across 11 cancer types, and gives you the industry's most accurate and actionable germline insights. Each patient's results are paired with professional and medical society guidelines, so you can quickly recommend the most effective surgical and treatment options.

Elevate patient care for those with cancer—and those needing preventive intervention

Treatment-focused reporting includes actionable summaries, with clear insights to help form screening, therapeutic, and surgical decisions

Industry-leading variant classification models for the accuracy you need[1]

Fast, simple workflow solutions provide pre- and post-test education and administrative support

Access to affordable testing and resources to help your patients navigate options

Expedited results within 2 weeks in most cases, with a 1-week priority for breast cancer, ensuring no delay in critical care

RiskScore® is the first and only PRS to include breast density that has been calibrated and clinically validated for all ancestries[2-4]

RiskScore provides 5-year and remaining lifetime risk estimates to guide future screening recommendations

PRS=polygenetic risk score; VUS=variant of uncertain significance.

Definitive answers, so you can clarify options and help improve outcomes

The lowest *BRCA1/2* VUS rate in the industry (1.2%)[5]



In one real-world example, **Myriad reclassified 54% of 79 *BRCA1/2* VUS** found by another lab

Including 1 suspected deleterious variant

Give your patients our lifetime commitment to VUS reclassification

9%
of amended reports impact medical management

60,000
VUS reclassifications over 10 years[6]

Customizable end-to-end workflow support that saves time and improves efficiency

1. **Patient identification**
   Tools to help determine who meets testing guidelines
2. **Pre-test Education**
   On-demand patient sessions with a certified genetic counselor
3. **Easy Ordering**
   Options include paper, online, virtual, and EMR
4. **Affordability**
   Transparent pricing, financial assistance, and other affordability options
5. **Results**
   Treatment-focused, comprehensive, and easy-to-follow results
6. **Post-test Education**
   Results follow-ups, scheduled or on-demand

MyRisk®
Hereditary Cancer Test

Affordable testing and personalized support for your patients

MyRisk STAT now includes Medicare and TriCare patients who meet criteria, ensuring more surgery pending patients have access to vital answers, fast

50+ Board-certified Genetic Counselors offer live pre- and post-test patient education and support for you and your patients, in 200+ languages, at no extra cost

95%
of private insurers cover MyRisk[7]

58%
of patients are eligible for financial assistance when needed[8]

90%
of patients testing with Myriad pay $0[7]

References:

1. Gradishar W, et al. Clinical variant classification: A comparison of public databases and a commercial testing laboratory. *The Oncologist*. 2017;22(7):797-803. doi:10.1634/theoncologist.2016-0431. **2.** Pruss D, et al. Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes. *Breast Cancer Res. Treat*. 2014;147(1):119-132. doi:10.1007/s10549-014-3065-9. **3.** Morris B, et al. Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm. *BMC Genet.* 2016;17(1). doi:10.1186/s12863-016-0407-0. **4.** Esterling L, et al. Impact of a cancer gene variant reclassification program over a 20-year period. *JCO Precis. Oncol.* 2020;(4):944-954. doi:10.1200/po.20.00020. **5.** Mundt E, et al. Driving Down the Rate of Variants of Uncertain Significance as the Myriad myRisk® Multigene Panel Grows [White paper]. Myriad Genetics. Oct 2019. **6.** Mersch J, et al. Prevalence of variant reclassification following Hereditary Cancer Genetic Testing. *JAMA*. 2018;320(12):1266. doi:10.1001/jama.2018.13152. **7.** Myriad internal data, 2023. **8.** Based on people who meet the U.S. Department of Health and Human Services federal poverty guidelines. Due to regulatory limitations, people who carry federally funded health insurance such as Medicare, Medicaid, TRICARE, and Medicare Advantage are not eligible for financial assistance. People with some types of Medicaid plans, including those with limited state-funded plans such as emergency-only coverage, or Medicaid in states that do not have coverage for Myriad testing, are eligible for the Myriad Financial Assistance Program; contact Myriad for details about your specific plan type.

Myriad® genetics

Myriad Genetics
332 North 2200 West
Salt Lake City, Utah 84116